Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00488774 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 291
- Enrollment target
NCT00488774 is a Phase 2 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 291 participants.
The verdict
NCT00488774, a Phase 2 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 291 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with active ulcerative colitis (UC) (sores in the colon).
Interventions
- OTHER Placebo
- DRUG Golimumab 1 mg per kg
- DRUG Golimumab 2 mg per kg
- DRUG Golimumab 4 mg per kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00488774
The ClinicalTrials.gov registry entry for NCT00488774 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00488774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00488774 about?
NCT00488774 is a clinical study titled "An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis". The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with active ulcerative colitis (UC) (sores in the colon).
What is the current status of trial NCT00488774?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 291 participants. The study started on 2007-08. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00488774?
The interventions under investigation include: Placebo (OTHER), Golimumab 1 mg per kg (DRUG), Golimumab 2 mg per kg (DRUG), Golimumab 4 mg per kg (DRUG).
Who is sponsoring clinical trial NCT00488774?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.